Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.
Department of Epidemiology and Cancer Control, St. Jude Children's Research Hospital, Memphis, Tennessee.
Transl Res. 2020 Jul;221:65-82. doi: 10.1016/j.trsl.2020.03.013. Epub 2020 May 1.
There are over 15 million survivors of cancer in the United States whose rates of frailty, an aging phenotype, range from just under 10% to over 80%. Frailty impacts not only disease survival but also long-term function and quality of life in children, adolescents, and in all adults diagnosed and/or treated for cancer. This review explains frailty as a construct and model of physiologic well-being. It also describes how frailty at diagnosis impacts cancer outcomes in adult populations and enumerates the prevalence of frailty in different populations of cancer survivors. Biological mechanisms responsible for aging and potentially for frailty among individuals with or who have been treated for cancer are discussed. Finally, promising pharmaceutical and lifestyle interventions designed to impact aging rather than a specific disease, tested in other populations, but likely applicable in cancer patients and survivors, are discussed.
在美国,有超过 1500 万名癌症幸存者,他们的脆弱程度(一种衰老表型)从略低于 10%到超过 80%不等。脆弱不仅影响疾病的生存,而且影响儿童、青少年和所有被诊断和/或治疗癌症的成年人的长期功能和生活质量。本综述解释了脆弱作为一种生理健康的结构和模型。它还描述了诊断时的脆弱如何影响成年人群的癌症结局,并列举了不同癌症幸存者群体中脆弱的患病率。讨论了导致癌症患者和治疗患者衰老和潜在脆弱的生物学机制。最后,讨论了一些有希望的药物和生活方式干预措施,这些措施旨在影响衰老而不是特定疾病,这些措施已经在其他人群中进行了测试,但可能适用于癌症患者和幸存者。